MIRA PHARMACEUTICALS, INC. Annual Report Summary

I’m here to help you break down Mira Pharmaceuticals’ latest annual report. Let’s look at what is happening with the company, the hurdles they face, and what the future might look like for your investment.

1. What does this company do?

Mira is a clinical-stage biotech company based in Miami, Florida. They currently have $0 in sales. They focus on research, aiming to develop FDA-approved treatments for chronic pain, neurological disorders, and addiction. Their business model relies on moving specialized compounds through the FDA’s drug approval process.

2. Their "Pipeline" (Products in development)

• Ketamir-2: This is their lead candidate, an oral ketamine analog for nerve pain. They finished initial safety studies and plan to start a Phase 2a clinical trial in early 2026.
• MIRA-55: A synthetic cannabinoid for inflammatory pain. It is currently in the early research stage, with animal studies underway to test dosing and safety.
• SKNY-1: Acquired in November 2025, this candidate targets GLP-1 receptors to treat obesity and nicotine addiction.

The DEA Factor: The DEA confirmed that Ketamir-2 and MIRA-55 are not controlled substances. This removes strict security requirements and simplifies the process for clinical trials and future distribution.

3. The "Secret Sauce" and Patent Risks

Since they have no sales, their value depends on their intellectual property. However, there are notable risks:

• The "Natural" Hurdle: Because their drugs are derived from natural chemical structures, the patent office is hesitant to grant broad patents. This forces Mira to rely on narrower, weaker patents that may not prevent competitors from developing similar products.
• Licensing Traps: Mira does not own its core technology; they license it from MIRALOGIX, a company controlled by the family trust of CEO Steve Gorlin. This structure means Mira’s research budget supports the CEO’s private holdings.
• The Royalty Burden: Mira must pay an 8% royalty on future sales of SKNY-1. They also owe a minimum of $250,000 in annual royalties once the drug hits the market, regardless of sales performance.

4. Financial Health: The "Burn"

Mira has not made a profit and has an accumulated loss of about $22.5 million.

• Rising Losses: Losses grew from $7.9 million in 2024 to $10.4 million in 2025, driven by higher research costs and acquisition fees.
• Dilution: To fund operations, the company sells more shares. In 2025, they issued 2.4 million new shares, which reduced the ownership percentage of existing shareholders.
• Future Funding: The company is running low on cash and management expects to raise more capital within the next year, which will likely result in further share dilution.

5. Operational Risks

• Legal Roadblocks: Shareholders are restricted to suing the company in one specific Florida court, which may limit legal options.
• Anti-Takeover Defenses: The board utilizes "poison pill" tactics to prevent hostile takeovers, which protects management from shareholder pressure even if the stock price declines.
• Virtual Office: The company operates out of a virtual office, which is an unconventional structure for a pharmaceutical firm managing complex lab work and data.
• Cybersecurity: Valuable chemical formulas and data are stored in the cloud, meaning a single security breach could compromise the company's competitive advantage.

Bottom Line: This is a high-risk, pre-revenue startup. Your investment depends entirely on their ability to successfully navigate clinical trials and secure partnerships before their current cash reserves are exhausted.